Mwyngil Therapeutics Launches Phase 1 Study for Neuroinflammatory Treatment Candidate BT-409 #United_States #Dover,_Delaware #Mwyngil_Therapeutics #BT-409 #NLRP3_Inhibitor
0
0
0
0
Mwyngil Therapeutics Launches Phase 1 Study for Neuroinflammatory Treatment Candidate BT-409 #United_States #Dover,_Delaware #Mwyngil_Therapeutics #BT-409 #NLRP3_Inhibitor
Insilico Medicine's ISM8969 Achieves IND Approval from FDA, Pioneering AI-Led Drug Development #United_States #Cambridge #Insilico_Medicine #NLRP3_Inhibitor #ISM8969
Insilico Medicine and Hygtia Therapeutics Team Up on Groundbreaking NLRP3 Inhibitor for CNS Diseases #None #Insilico_Medicine #Hygtia_Therapeutics #NLRP3_Inhibitor